Download DNB 2020 June Rheumatology Paper III Question Paper

Download Diplomate of National Board (DNB) 2020 June Rheumatology Paper III Question Paper

FINAL EXAM
NATIONAL BOARD OF EXAMINATIONS
JUNE 2020
RHEUMATOLOGY
PAPER-II
Time: 3 hours
RHM/J/20/43/III
Max. Marks:100
Important Instructions:
Attempt al questions in order.
Each question carries 10 marks.
Read the question careful y and answer to the point neatly and legibly.
Do not leave any blank pages between two answers.
Indicate the question number correctly for the answer in the margin space.
Answer al the parts of a single question together.
Start the answer to a question on a fresh page or leave adequate space between two answers.
Draw table/diagrams/flowcharts wherever appropriate.
Write short notes on:
1. What is vascular Behcet's syndrome? Write its pathogenesis and various 2+4+4
manifestations. What are the various therapeutic approaches?
2. Discuss ILAR classification of juvenile arthritis? What are the problems with
5+3+2
it? Is there a need to modify the classification?
3. What are the major mechanisms involved in the pathogenesis of
6+4
Neuropsychiatric lupus? How does it impact the approach to patient with
neuropsychiatric lupus?
4. Discuss management of a patient with active Takayasu's arteritis. What is
6+4
the role of endovascular intervention?
5. What are the indications of hip joint replacement? When do you prefer a
3+2+5
non-cemented hip prosthesis? What are the long term complications?
6. Discuss rheumatological manifestation seen in patients with primary
7+3
immunodeficiency? What are the clinical features of DADA-2.
7. Discuss different T helper cel subsets? How can you increase T regulatory
4+6
cel s to reset the balance in patients with autoimmune diseases?
8. What are the causes of foot pain? Write chal enges and management of foot
3+2+5
pain.
9. What is the importance of detecting ANA subspecificities? Discuss clinical
3+5+2
association of these autoantibodies? Name 2 methods used to test these
autoantibodies.
10. Discuss therapies targeted at type I interferon pathway in SLE and
7+3
autoinflammatory diseases.
************
POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE
EXAMINATION HALL.

---